Journal
INFECTION
Volume 49, Issue 4, Pages 757-762Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s15010-021-01606-9
Keywords
COVID-19; SARS-CoV-2; CD169; SIGLEC1; Type I interferons
Categories
Funding
- German Research Foundation [SFB-TR84 C8, SFB-TR84 C6, SFB-TR84 C9]
- German Ministry of Education and Research [01KI07114, 01KI20160A, 01KX2021]
- CAPSyS project [01ZX1304B, 01ZX1604B]
Ask authors/readers for more resources
In patients with COVID-19, higher monocytic CD169/SIGLEC1 expression levels were found in those with mild disease compared to severe cases. Further clinical studies are recommended to evaluate the value of CD169/SIGLEC1 expression in patients with COVID-19 with or without auto-antibodies against type I interferons.
Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I interferons are important in the defense of viral infections. Recently, neutralizing IgG auto-antibodies against type I interferons were found in patients with severe COVID-19 infection. Here, we analyzed expression of CD169/SIGLEC1, a well described downstream molecule in interferon signaling, and found increased monocytic CD169/SIGLEC1 expression levels in patients with mild, acute COVID-19, compared to patients with severe disease. We recommend further clinical studies to evaluate the value of CD169/SIGLEC1 expression in patients with COVID-19 with or without auto-antibodies against type I interferons.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available